402 related articles for article (PubMed ID: 26026072)
1. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.
Lee P; Murphy B; Miller R; Menon V; Banik NL; Giglio P; Lindhorst SM; Varma AK; Vandergrift WA; Patel SJ; Das A
Anticancer Res; 2015 Feb; 35(2):615-25. PubMed ID: 25667438
[TBL] [Abstract][Full Text] [Related]
3. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
4. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Feng W; Zhang B; Cai D; Zou X
Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
8. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat.
Zagni C; Floresta G; Monciino G; Rescifina A
Med Res Rev; 2017 Nov; 37(6):1373-1428. PubMed ID: 28181261
[TBL] [Abstract][Full Text] [Related]
9. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
[TBL] [Abstract][Full Text] [Related]
10. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
11. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors in the treatment of hematological malignancies.
Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
Koutsounas I; Giaginis C; Theocharis S
World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
18. Current evidence for histone deacetylase inhibitors in pancreatic cancer.
Koutsounas I; Giaginis C; Patsouris E; Theocharis S
World J Gastroenterol; 2013 Feb; 19(6):813-28. PubMed ID: 23430136
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer.
Xiang XS; Li PC; Wang WQ; Liu L
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188676. PubMed ID: 35016922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
